Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 11,372 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Terminated Phase 2 Interventional

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

NCT00272181
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Head and Neck Cancer
Interventions
Proxinium
Drug
Lead sponsor
Sesen Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 29, 2026, 2:30 PM EDT
Recruiting No phase listed Observational

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

NCT07677267
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 115 Years · Male only
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed No phase listed Observational

The Loop Observational Study

NCT03838900
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Loop
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Not listed
Enrollment
1,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

NCT00578071
View directory record Official record
Conditions
Cancer of the Esophagus
Interventions
Panitumumab, Capecitabine, Oxaliplatin, Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Brian Czito
Other
Eligibility
18 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

NCT06488209
View directory record Official record
Conditions
Healthy Volunteers, Autoimmune Disease
Interventions
LAD191, Placebo
Drug · Other
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Miami, Florida • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults

NCT05547399
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zanubrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 29, 2026, 2:30 PM EDT
Active, not recruiting No phase listed Observational

Effects of Transitional Circulation in ELBW Infants

NCT02016599
View directory record Official record
Conditions
Neonatal Prematurity, Hypotension
Interventions
Monitoring and biospecimen collection
Other
Lead sponsor
University of Iowa
Other
Eligibility
Up to 1 Week
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

NCT03661632
View directory record Official record
Conditions
Advanced Cancer
Interventions
BMS-986310, Nivolumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
St Louis, Missouri • Hackensack, New Jersey • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 29, 2026, 2:30 PM EDT
Terminated Phase 1 Interventional

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

NCT04464798
View directory record Official record
Conditions
Lymphoma
Interventions
CC-220, Rituximab, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00748501
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SB-509
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
La Jolla, California • Orange, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 29, 2026, 2:30 PM EDT
Terminated Phase 1 Interventional Results available

A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

NCT04740034
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
AMG 340
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 29, 2026, 2:30 PM EDT
Completed No phase listed Observational

KidneyCare Cohort Study (KCC-S)

NCT06898632
View directory record Official record
Conditions
Kidney Cancer
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

NCT01105598
View directory record Official record
Conditions
Mild Dyslipidemia
Interventions
ETC-1002 or placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Results available

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

NCT00941863
View directory record Official record
Conditions
Carcinoma
Interventions
Sorafenib 100 mg (50-mg tablet), Sorafenib 200 mg (50-mg tablet), Sorafenib 400 mg (50-mg tablet), Sorafenib 400 mg (200-mg tablet), Sorafenib 400 mg (Expansion)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 29, 2026, 2:30 PM EDT
Not listed No phase listed Observational

Effectiveness of Smoking Cessation Program in a Community Health System

NCT05107687
View directory record Official record
Conditions
Smoking Cessation
Interventions
Smoking cessation
Behavioral
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
CYT387
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer

NCT01440816
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures

NCT01526265
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Usual Care, Individual Rewards, Fixed Deposits, Competitive Deposits (Pari-Mutuel), Collaborative Rewards
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2,185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional

Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma

NCT03793907
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
FitBit, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training, STEPS to Enhance Physical Activity
Device · Other · Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 29, 2026, 2:30 PM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

NCT01849744
View directory record Official record
Conditions
Non Hematologic Cancers, Metastatic Cancer
Interventions
VS-4718
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 29, 2026, 2:30 PM EDT
Active, not recruiting No phase listed Observational

Multicenter Orthopaedics Outcomes Network for ACL Reconstructions

NCT00463099
View directory record Official record
Conditions
Rupture of Anterior Cruciate Ligament
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 80 Years
Enrollment
3,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2028
U.S. locations
8
States / cities
Boulder, Colorado • Iowa City, Iowa • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

NCT01045863
View directory record Official record
Conditions
Healthy
Interventions
PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma

NCT00862901
View directory record Official record
Conditions
Breast Cancer, Skin Cancer
Interventions
CLIPT patch
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 29, 2026, 2:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of NEO-201 in Solid Tumors Expansion Cohorts

NCT03476681
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
Interventions
NEO-201 in combination with pembrolizumab
Drug
Lead sponsor
Precision Biologics, Inc
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 29, 2026, 2:30 PM EDT